Dihydropyridine calcium channel blocker drugs - nifedipine

Last updated on October 6, 2022

Special Authority requests can now be submitted online. It's simple and quick!

Generic name		nifedipine
Strength		20 mg, 30 mg, 60 mg
Form		extended release tablet

Criteria	Approval period
1. Treatment failure on optimal dose of, or intolerance to, amlodipine. OR 2. Complex patient requiring medications for co-existing chronic condition(s).	Indefinite

Criteria

Approval period

1. Treatment failure on optimal dose of, or intolerance to, amlodipine.

2. Complex patient requiring medications for co-existing chronic condition(s).

Indefinite

Practitioner exemptions

Practitioners in the following specialty are not required to submit a Special Authority request form for coverage:

Cardiologists
Cardiovascular and Thoracic Surgery
Internists specializing in cardiology
Nephrologists
Paediatrics
Paediatric Cardiology

Special notes

Immediate-release nifedipine capsules will be covered by Special Authority only for a person with a diagnosis of vasospastic angina (Prinzmetal angina).
Patients with co-existing chronic conditions requiring use of multiple medications will be considered complex for the purposes of Special Authority criteria.

Special Authority request form(s)

Log in to eForms
5328—General Special Authority Request

Did you find what you were looking for?

The B.C. Public Service acknowledges the territories of First Nations around B.C. and is grateful to carry out our work on these lands. We acknowledge the rights, interests, priorities, and concerns of all Indigenous Peoples - First Nations, Métis, and Inuit - respecting and acknowledging their distinct cultures, histories, rights, laws, and governments.

More topics

Dihydropyridine calcium channel blocker drugs - nifedipine

Practitioner exemptions

Special notes

Special Authority request form(s)